keyword
MENU ▼
Read by QxMD icon Read
search

Multiple myeloma, young patient

keyword
https://www.readbyqxmd.com/read/27922862/improved-detection-of-minimal-residual-disease-by-11c-methionine-pet-ct-in-a-young-patient-with-unusual-extramedullary-presentation-of-recurrent-multiple-myeloma
#1
Carmelo Caldarella, Salvatore Annunziata, Livio Pagano, Valerio De Stefano, Vittoria Rufini
Extramedullary relapse of multiple myeloma (MM) is uncommon. A 40-year-old woman with history of MM underwent PET/CT using C-methionine (C-MET) after the detection of a vulvar lesion on MRI, biopsy proven to be extramedullary relapse of MM. The vulvar lesion was negative at the F-FDG PET/CT but showed high uptake of C-MET; focal uptake of both F-FDG and C-MET was shown within the muscles of the left leg, histologically confirmed as extramedullary relapse of MM. F-FDG PET/CT performed after chemotherapy showed no uptake in both sites, whereas posttreatment C-MET PET/CT showed persistence of residual uptake within the vulvar lesion...
December 3, 2016: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27863287/bone-health-in-the-elderly-cancer-patient-a-siog-position-paper
#2
REVIEW
J J Body, E Terpos, B Tombal, P Hadji, A Arif, A Young, M Aapro, R Coleman
More than a third of cancers are diagnosed in people over the age of 75. Androgen deprivation for prostate cancer and aromatase inhibitors in breast cancer accelerate age-related bone loss and increase fracture rates. BMD should be checked by dual energy X-ray absorptiometry at baseline and, dependent on risk, every 12-24months. Sufficient calcium, vitamin D and exercise are part of primary fracture prevention. Resistance exercise in particular may improve functional activity and bone density. In men at increased fracture risk and women with postmenopausal early breast cancer, antiresorptive treatment is warranted to reduce fracture rate and to increase overall survival in breast cancer...
December 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/27795516/treatment-strategy-in-untreated-transplant-eligible-multiple-myeloma-patients
#3
Kazutaka Sunami
Autologous stem cell transplantation (ASCT) is known to be superior to conventional chemotherapies and has been established as a standard of care for young patients with multiple myeloma. In the first decade of this century, novel agents such as thalidomide, bortezomib, and lenalidomide became clinically available, and several clinical trials using these drugs as induction therapies, conditioning regimens, and post-transplant consolidation and maintenance therapies have been reported, leading to increasing improvement in treatment results as compared to conventional therapies...
2016: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/27764795/a-novel-3d-mesenchymal-stem-cell-model-of-the-multiple-myeloma-bone-marrow-niche-biologic-and-clinical-applications
#4
Jana Jakubikova, Danka Cholujova, Teru Hideshima, Paulina Gronesova, Andrea Soltysova, Takeshi Harada, Jungnam Joo, Sun-Young Kong, Raphael E Szalat, Paul G Richardson, Nikhil C Munshi, David M Dorfman, Kenneth C Anderson
Specific niches within the tumor bone marrow (BM) microenvironment afford a sanctuary for multiple myeloma (MM) clones due to stromal cell-tumor cell interactions, which confer survival advantage and drug resistance. Defining the sequelae of tumor cell interactions within the MM niches on an individualized basis may provide the rationale for personalized therapies. To mimic the MM niche, we here describe a new 3D co-culture ex-vivo model in which primary MM patient BM cells are co-cultured with mesenchymal stem cells (MSC) in a hydrogel 3D system...
October 13, 2016: Oncotarget
https://www.readbyqxmd.com/read/27641727/vemurafenib-in-combination-with-cobimetinib-in-relapsed-and-refractory-extramedullary-multiple-myeloma-harboring-the-braf-v600e-mutation
#5
Ulrich J M Mey, Christoph Renner, Roger von Moos
BRAF mutations are present in a variety of cancers and cause constitutive activation of the Ras-Raf-MEK-ERK signaling pathway. In cutaneous malignant melanoma, combined treatment with BRAF and MEK inhibitors is associated with high response rates and has been shown to improve progression free as well as overall survival compared to BRAF inhibition alone. In multiple myeloma, BRAF mutations are detectable only in a minority of patients. Only few data are available regarding the clinical activity of BRAF inhibitors in BRAF-positive multiple myeloma patients, including some anecdotal reports on remarkable responses in individuals being resistant to all other available anti-myeloma treatment approaches...
September 19, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27548407/impact-of-marital-status-insurance-status-income-and-race-ethnicity-on-the-survival-of-younger-patients-diagnosed-with-multiple-myeloma-in-the-united-states
#6
Luciano J Costa, Ilene K Brill, Elizabeth E Brown
BACKGROUND: Recent advances in the treatment of multiple myeloma (MM) have been associated with improved survival, predominantly among young and white patients. The authors hypothesized that sociodemographic factors, adjusted for race/ethnicity, influence the survival of younger patients with MM. METHODS: Overall survival (OS) data were obtained for individuals included in the Surveillance, Epidemiology, and End Results (SEER-18) program who were diagnosed with MM before the age of 65 years between 2007 and 2012...
October 15, 2016: Cancer
https://www.readbyqxmd.com/read/27536655/amyloid-arthropathy-of-the-hip-joint-associated-with-multiple-myeloma-a-case-report
#7
Yoon Je Cho, Young Soo Chun, Kee Hyung Rhyu, Yong Koo Park, Kyung Nam Ryu, Ji Seon Park, Huo Liang, Gwang Young Jung, Won Ju Shin
Amyloidosis is a disease characterized by the deposition of non-soluble fibrous protein in multiple tissues with a number of possible causes. This protein deposition can occur in any tissue, yet is most commonly seen in kidneys, heart, and gastrointestinal tracts. However, invasion to bone tissues is not often reported. The deposition of amyloid proteins in bone tissues may result in joint pain and pathological fractures; it is important to elucidate the causes and detect early to determine prognosis and treat optimally...
June 2016: Hip & Pelvis
https://www.readbyqxmd.com/read/27421913/diagnostic-performances-of-m-protein-tests-according-to-the-clinical-presentations-of-kidney-disease
#8
Eun Hee Koo, Jung-Ho Shin, Hye Ryoun Jang, Hyung-Doo Park, Gee-Young Kwon, Wooseong Huh, Dae Joong Kim, Yoon-Goo Kim, Ha Young Oh, Jung Eun Lee
BACKGROUND: Screening for monoclonal immunoglobulin (MIg) is critical in patients with kidney disease. METHODS: We identified 943 subjects who underwent kidney biopsy and at least one of monoclonal (M)-protein tests (serum and urine electrophoresis [EP], serum and urine immunofixation [IF], and serum free light chain [FLC] ratio). The sensitivities of several combinations of the 5 tests were examined by clinical presentations of kidney disease. RESULTS: The sensitivities of serum EP, urine EP, and the serum FLC ratio were 65%, 68%, and 71%, respectively, which were lower than those of serum IF (79%) and urine IF (87%) to detect MIg...
September 2016: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/27365142/thalidomide-based-induction-regimens-are-as-effective-as-bortezomib-based-regimens-in-elderly-patients-with-multiple-myeloma-with-cereblon-expression
#9
Sung-Hoon Jung, Hyun-Jung Choi, Myung-Geun Shin, Seung-Shin Lee, Eu Chang Hwang, Tae-Young Jung, Min-Seok Cho, Deok-Hwan Yang, Jae-Sook Ahn, Yeo-Kyeoung Kim, Hyeoung-Joon Kim, Je-Jung Lee
Cereblon (CRBN) has been identified as a primary target of immunomodulatory drugs and is considered a biomarker for the prediction of outcomes after thalidomide- or lenalidomide-based treatments. In this study, we evaluated CRBN expression in bone marrow (BM) tissue at diagnosis and investigated the relationship between CRBN expression and treatment outcomes after thalidomide- or bortezomib-based front-line therapies in 89 elderly patients with multiple myeloma (MM). CRBN expression at the time of diagnosis was evaluated with immunohistochemical (IHC) staining for myeloma cells in paraffin wax-embedded BM tissue...
October 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27358777/first-line-vs-delayed-transplantation-in-myeloma-certainties-and-controversies
#10
REVIEW
Annamaria Brioli
Since the middle of 1990s autologous stem cell transplantation has been the cornerstone for the treatment of young patients with multiple myeloma (MM). In the last decade the introduction of novel agents such as immunomodulatory drugs (IMiDs) and proteasome inhibitors (PI), has dramatically changed the therapeutic scenario of this yet incurable disease. Due to the impressive results achieved with IMiDs and PI both in terms of response rates and in terms of progression free and overall survival, and to the toxicity linked to high dose therapy and autologous stem cell transplantation (ASCT), a burning question nowadays is whether all young patients should be offered autotransplantation up front or if this should be reserved for the time of relapse...
June 24, 2016: World Journal of Transplantation
https://www.readbyqxmd.com/read/27349765/cyclophosphamide-and-bortezomib-with-prednisone-or-dexamethasone-for-the-treatment-of-relapsed-and-refractory-multiple-myeloma
#11
Donna E Reece, Young Trieu, Esther Masih-Khan, Eshetu G Atenafu, Christine Chen, Anca Prica, Rodger Tiedemann, Suzanne Trudel, Vishal Kukreti
INTRODUCTION: Cyclophosphamide, bortezomib, and prednisone (CyBorP) is a highly effective, well-tolerated regimen in relapsed/refractory multiple myeloma. CyBorP, originally developed at our center to include weekly bortezomib (Bor) and alternate-day prednisone (P), was recently modified so that weekly dexamethasone (D) replaced prednisone. PATIENTS AND METHODS: To assess the effectiveness and tolerability of CyBorP/D in real-world practice, we identified 96 relapsed/refractory patients who received ≥ 1 28-day cycle of CyBorP/D, consisting of cyclophosphamide 300 mg/m(2) (days 1, 8, 15, and 22), Bor 1...
July 2016: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/27342591/circulating-immune-cell-phenotype-can-predict-the-outcome-of-lenalidomide-plus-low-dose-dexamethasone-treatment-in-patients-with-refractory-relapsed-multiple-myeloma
#12
Sung-Eun Lee, Ji-Young Lim, Da-Bin Ryu, Tae Woo Kim, Jae-Ho Yoon, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Seok Lee, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Myungshin Kim, Chang-Ki Min
Although the antimyeloma effect of lenalidomide is associated with activation of the immune system, the exact in vivo immunomodulatory mechanisms of lenalidomide combined with low-dose dexamethasone (Len-dex) in refractory/relapsed multiple myeloma (RRMM) patients remain unclear. In this study, we analyzed the association between immune cell populations and clinical outcomes in patients receiving Len-dex for the treatment of RRMM. Peripheral blood samples from 90 RRMM patients were taken on day 1 of cycles 1 (baseline), 2, 3, and 4 of Len-dex therapy...
August 2016: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/27284562/extramedullary-plasmacytoma-of-the-oral-cavity-in-a-young-man-a-case-report
#13
Narges Gholizadeh, Masoumeh Mehdipour, Bita Rohani, Vahid Esmaeili
Extramedullary plasmacytomas are rare solitary soft tissue tumors that arise from proliferations of malignant transformed monoclonal plasma cells and can be diagnosed through biopsy and histopathologic examination. These lesions are closely associated with multiple myelomas, which should be ruled out in all these cases by necessary laboratory and radiographic examinations. A 25-year-old man was referred to our clinic with a rapidly-growing painless lesion measuring about 2.5×3×3 cm in the palatal side of the left maxillary second and third molar teeth...
June 2016: Journal of Dentistry
https://www.readbyqxmd.com/read/27221891/international-scoring-system-in-symptomatic-multiple-myeloma-experience-from-a-tertiary-care-center
#14
Sadia Sultan, Syed Mohammed Irfan, Saira Parveen, Ufaq Taufiq
BACKGROUND: Symptomatic multiple myeloma (MM) is an acquired B-cell malignant proliferation of anti- body secreting plasma cells, characterized by end organ damage due to monoclonal immunoglobulin secretion. The aim of this study wa to determine the stage stratification according to an international scoring system in adult Pakistani MM patients at presentation. MATERIALS AND METHODS: This single centre retrospective study extendedfrom January 2012 to December 2015...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/27221861/multiple-myeloma-a-retrospective-analysis-of-61-patients-from-a-tertiary-care-center
#15
Sadia Sultan, Syed Mohammed Irfan, Saira Parveen, Hamza Ali, Maria Basharat
BACKGROUND: Multiple myeloma (MM) is an acquired clonal B-cell malignancy which primarily affects elderly individuals with an annual incidence of approximately 1% of all malignancies. Our aim is to study demographic and clinicopathological features of adult Pakistani MM patients at presentation. MATERIALS AND METHODS: This single centre retrospective study extended from January 2010 to December 2014. Data were retrieved from the patients' maintained records on predetermined performa...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/27079282/concomitant-multiple-myeloma-spectrum-diagnosis-in-a-central-retinal-vein-occlusion-a-case-report-and-review
#16
REVIEW
Christopher J Borgman
Multiple myeloma is a neoplastic plasma-cell disorder resulting from malignant plasma cells in the bone marrow. It can cause a hyperviscosity syndrome secondary to the paraproteinaemia associated with the disease. The increased hyperviscosity can lead to retinal vein occlusions and other ocular problems that may challenge clinicians. In patients with multiple myeloma and hypertension and/or diabetes mellitus, retinal changes appear similar and changes due to one disease or the other may be difficult to determine...
July 2016: Clinical & Experimental Optometry: Journal of the Australian Optometrical Association
https://www.readbyqxmd.com/read/27052989/the-clinical-impact-of-thalidomide-maintenance-after-autologous-stem-cell-transplantation-in-patients-with-newly-diagnosed-multiple-myeloma-in-real-clinical-practice-of-korea
#17
Ho Sup Lee, Chang-Ki Min, Je-Jung Lee, Kihyun Kim, Seok Jin Kim, Dok Hyun Yoon, Hyeon-Seok Eom, Hyewon Lee, Won Sik Lee, Ho-Jin Shin, Ji Hyun Lee, Yong Park, Jae-Cheol Jo, Young Rok Do, Yeung-Chul Mun, Mark Hong Lee
In real clinical settings (not clinical trials), thalidomide has been accepted as maintenance therapy to patients with multiple myeloma (MM) because of the cost of drugs, the limitations of medical insurance, etc., in our country (South Korea). The purpose of this study was to evaluate the utility of thalidomide maintenance for improving survival in transplantation-eligible patients with MM in the real clinical field. Differences in survival rates were estimated in patients treated with or without thalidomide maintenance...
May 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27051233/pretreatment-lymphopenia-poor-performance-status-and-early-courses-of-therapy-are-risk-factors-for-severe-bacterial-infection-in-patients-with-multiple-myeloma-during-treatment-with-bortezomib-based-regimens
#18
Shin Young Hyun, Sang Hoon Han, Soo-Jeong Kim, Ji Eun Jang, Yundeok Kim, Hyunsoo Cho, Jung Yeon Lee, June-Won Cheong, Yoo Hong Min, Jae-Woo Song, Jin Seok Kim
The aim of this study was to identify the risk factors associated with severe bacterial infection (SBI) in multiple myeloma (MM) patients during treatment with bortezomib-based regimens. A total of 98 patients with MM were evaluated during 427 treatment courses. SBI occurred in 57.1% (56/98) of the patients and during 19.0% (81/427) of the treatment courses. In the multivariate analysis for the factors associated with the development of SBI in each treatment course, poor performance status (Eastern Cooperative Oncology Group ≥ 2, P < 0...
April 2016: Journal of Korean Medical Science
https://www.readbyqxmd.com/read/27015231/burden-of-cytogenetically-abnormal-plasma-cells-in-light-chain-amyloidosis-and-their-prognostic-relevance
#19
Seon Young Kim, Kyongok Im, Si Nae Park, Jung-Ah Kim, Sung-Soo Yoon, Dong Soon Lee
We performed cytoplasmic fluorescence in situ hybridization assays of light chain amyloidosis (AL). In total, 234 patients were enrolled: 28 patients with AL, 24 with monoclonal gammopathy of undetermined significance (MGUS), and 182 with multiple myeloma (MM). Chromosomal abnormalities were detected in 13 of 22 (59%) AL patients without MM. All 13 patients demonstrated IGH rearrangement, and t(11;14)/IGH-CCND1 was most frequent (32%). Chromosome gain was not observed in AL patients without MM. These findings were dissimilar to findings in MGUS patients, in whom trisomy 9 was the most frequent abnormality...
May 2016: Leukemia Research
https://www.readbyqxmd.com/read/27012957/oral-proteasome-inhibitor-with-strong-preclinical-efficacy-in-myeloma-models
#20
Jonghoon Park, Eok Park, Cheol-Kyu Jung, Seung-Wan Kang, Byung Gyu Kim, Youngjoo Jung, Tae Hun Kim, Ji-Young Lim, Sung-Eun Lee, Chang-Ki Min, Kwang-Ai Won
BACKGROUND: The proteasome is a validated anti-cancer target and various small-molecule inhibitors are currently in clinical development or on the market. However, adverse events and resistance associated with those proteasome inhibitors indicate the need for a new generation of drugs. Therefore, we focused on developing an oral proteasome inhibitor with improved efficacy and safety profiles. METHOD: The in vitro inhibition of the 20S proteasome catalytic activities was determined in human multiple myeloma (MM) cellular lysates with fluorogenic peptide substrates specific for each catalytic subunit...
2016: BMC Cancer
keyword
keyword
108669
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"